Fenofibrate and Diabetic Retinopathy.
Fenofibrate and Diabetic Retinopathy.
复制标题
DOI:
10.1007/s11892-016-0786-7
复制
发表时间:
2016-10
影响因子:
4.2
通讯作者:
Chew EY
中科院分区:
文献类型:
--
作者:
Knickelbein JE;Abbott AB;Chew EY
Diabetic retinopathy, a common and sight-threatening microvascular complication of diabetes mellitus, is a leading cause of blindness among working-aged adults. Medical therapies including intensive control of hyperglycemia and hypertension have been shown to reduce the incidence and progression of diabetic retinopathy. The association of dyslipidemia and treatment with statins with diabetic retinopathy is inconsistent in epidemiologic studies. However, two recent randomized clinical trials have demonstrated beneficial effects of systemic fenofibrate therapy in reducing the progression of diabetic retinopathy independently of serum lipid levels. These findings suggest that fenofibrate may be an effective strategy for reducing the progression of diabetic retinopathy, thus reducing the large and growing public health burden of treating the sight-threatening complications of diabetic retinopathy.
登录
查看更多内容
影响因子:
5.1
作者:
Guariguata, L.;Whiting, D. R.;Shaw, J. E.
通讯作者:
Shaw, J. E.
影响因子:
16.2
作者:
Mychaleckyj JC;Craven T;Nayak U;Buse J;Crouse JR;Elam M;Kirchner K;Lorber D;Marcovina S;Sivitz W;Sperl-Hillen J;Bonds DE;Ginsberg HN
通讯作者:
Ginsberg HN
DOI:
10.1056/nejmoa1001288
发表时间:
2010-07-15
期刊:
The New England journal of medicine
影响因子:
--
作者:
ACCORD Study Group;ACCORD Eye Study Group;Chew EY;Ambrosius WT;Davis MD;Danis RP;Gangaputra S;Greven CM;Hubbard L;Esser BA;Lovato JF;Perdue LH;Goff DC Jr;Cushman WC;Ginsberg HN;Elam MB;Genuth S;Gerstein HC;Schubart U;Fine LJ
通讯作者:
Fine LJ
影响因子:
--
作者:
KLEIN, R;KLEIN, BEK;DEMETS, DL
通讯作者:
DEMETS, DL
影响因子:
168.9
作者:
Keech, A. C.;Mitchell, P.;Colman, P. G.
通讯作者:
Colman, P. G.